

---

# TEN YEARS OF TEAMWORK

---

EST 2013



**BIG** | **CANCER  
RESEARCH  
CONSORTIUM**



Access  
Network: Hilton Honors Meeting  
Password: bigter

Wi-fi Access  
Network: Hilton Honors Meeting  
BIO

Sharon  
Sharon Moore  
BIO

BIREN  
SARAYIA  
RUTBER

Mridula  
Mridula George  
BIO



# BIG TEN CANCER RESEARCH CONSORTIUM

---

## TABLE OF CONTENTS

---

### INTRODUCTION

Message from <b>The Cancer Center Directors</b>	4
--	---

### LEADERSHIP

Directors	6
Steering <b>Committee</b>	7

### OVERVIEW

Big Ten Cancer Research Consortium <b>At a Glance</b>	8
--	---

### DEVELOPMENT

Big Ten Cancer Research Consortium <b>Mission &amp; Vision</b>	10
---	----

### HISTORY

Big Ten Cancer Research Consortium <b>10 years</b>	12
---	----

### INSTITUTIONAL MILESTONES

Ten Years of <b>Innovation</b>	14
--------------------------------	----

### CLINICAL TRIALS

Clinical Trial <b>Working Groups</b>	16
Clinical Trials	18

### PUBLICATIONS

Meeting <b>Posters &amp; Presentations</b>	20
Journal <b>Manuscripts</b>	21

### INITIATIVES

10 Years of <b>Collaboration</b>	22
Big Ten CRC <b>Diversity Committee</b>	23

---

MESSAGE FROM THE CHAIR  
**CANCER CENTER DIRECTORS**

---

Howard Bailey, MD



Dear friends and colleagues:

As the Director of the University of Wisconsin Carbone Cancer Center, I am honored to be a part of the remarkable journey of the Big Ten Cancer Research Consortium and to witness the profound impact we have made together in the fight against cancer.

Ten years ago, our consortium was founded on the shared belief that by bringing together the brightest minds from our member institutions, we could accelerate progress in cancer research and improve outcomes for patients across the Big Ten region and beyond. Today, I am proud to say that we have exceeded our wildest expectations.

Over the past decade, the Big Ten Cancer Research Consortium has been at the forefront of groundbreaking discoveries, innovative clinical trials, and transformative advancements in cancer care. Together, we have not only pushed the boundaries of scientific knowledge but also delivered real hope and tangible benefits to countless individuals and families affected by this devastating disease.

As we commemorate this milestone, I want to express my heartfelt gratitude to all of you who have been instrumental in making our consortium's achievements possible.



To our dedicated researchers, clinicians, nurses, and support staff who work tirelessly each day to advance the field of oncology, thank you for your unwavering commitment to our shared mission. To the patients and their families who have participated in our clinical trials, your courage and resilience inspire us all.

I also want to recognize the invaluable contributions of our industry collaborators. Our shared commitment and our collective expertise have been the driving force behind our success. Together, we have forged a network of excellence that continues to redefine the future of cancer research and care.

Our commitment to innovation, collaboration, and the relentless pursuit of a cancer-free world remains unwavering. With your continued support and dedication, there is no doubt we will achieve even greater heights in the years to come.

Thank you once again for being part of this remarkable journey. Together, we are making a profound difference in the lives of cancer patients, and I am excited to see what we will accomplish in the next decade and beyond.



HOWARD BAILEY, MD


Chair, Cancer Center Directors  
Director, University of Wisconsin Carbone  
Cancer Center



---

## BIG TEN CRC LEADERSHIP


---



### **HOWARD BAILEY, MD**

#### **Chair, Cancer Center Directors**

Howard Bailey, MD, is the director of the University of Wisconsin Carbone Cancer Center and a professor of Medicine at the UW School of Medicine and Public Health. Dr. Bailey's clinical expertise is in sarcomas and gynecologic malignancies and his research focus is in anti-cancer drug development, especially chemoprevention, and research network development. Dr. Bailey also leads the UWCCC Chemoprevention Scientific Program and Chemoprevention Disease Orientated Work Group. He was appointed to the national committee which reviews all NCI-designated Cancer Centers in 2011.



### **RAPHAEL POLLOCK, MD, PHD**

#### **Chair, Big Ten Cancer Research Consortium Foundation, Inc.**

Raphael Pollock, MD, PhD, serves as director of The Ohio State University Comprehensive Cancer Center, professor in Ohio State's Division of Surgical Oncology and holder of the Klotz Chair in Cancer Research. Dr. Pollock also serves as director of The Ohio State University Sarcoma Research Laboratory. Dr. Pollock has authored or co-authored more than 400 original research and review articles, as well as 21 books. Dr. Pollock has shared his work in over 300 national and international presentations and visiting professorships involving professional audiences in more than 50 countries worldwide.



### **MONIKA JOSHI, MD, MRCP**

#### **Chief Scientific Officer**

Monika Joshi, MD, MRCP, is a professor in the Division of Hematology-Oncology in Department of Medicine at the Penn State Cancer Institute (PSCI). She serves as disease team co-leader for the genitourinary diseases group at the PSCI and as medical director for the PSCI Clinical Trials Office. Her clinical and research interests lie primarily in the field of genitourinary tumors, particularly in the field of immunotherapy and targeted therapy. She has an interest in developing clinical trials with novel immunotherapeutic combinations and identifying predictive and prognostic biomarkers. Dr. Joshi has been active in the Big Ten CRC since the consortium's founding in 2013. In addition to leading multiple Big Ten CRC studies, she has served on the Big Ten CRC Steering Committee and as a co-chair the Genitourinary Clinical Trial Working Group.

---

# STEERING COMMITTEE

---



**Oana  
Danciu, MD**

University of Illinois  
Cancer Center




**Timothy  
Fan, PhD, DVM**

The Cancer  
Center at Illinois



**Nabil Adra, MD**

Indiana University Melvin  
and Bren Simon  
Comprehensive Cancer  
Center



**Muhammad  
Furqan, MD**

University of Iowa Holden  
Comprehensive Cancer Center



**Vu Hong  
Duong, MD, MS**

University of Maryland  
Marlene and Stewart  
Greenbaum Comprehensive  
Cancer Center



**Christopher Lao,  
MD**

University of Michigan Rogel  
Cancer Center



**Craig Emmitt Cole,  
MD**

Michigan State  
University Cancer Research



**Veronika Bachanova,  
MD, PhD**

Masonic Cancer  
Center, University of Minnesota



**Vijaya Raj  
Bhatt, MBBS, MS**

Fred & Pamela Buffett Cancer  
Center (University of Nebraska)




**Jyoti Patel, MD**

Robert H. Lurie  
Comprehensive Cancer Center  
of Northwestern University



**John L. Hays, MD,  
PhD**

The Ohio State University  
Comprehensive Cancer Center




**Patrick C.  
Ma, MD, MSc**

Penn State Cancer Institute



**Thomas G.  
Sors, PhD**

Purdue University  
Center for Cancer Research



**Salma Jabbour, MD**

Rutgers Cancer  
Institute of New Jersey



**Kari Wisinski, MD**

University of  
Wisconsin Carbone Cancer  
Center

---

## BIG TEN CRC AT A GLANCE

---

### COMPETITORS ON THE FIELD, PARTNERS IN CURING CANCER

The Big Ten CRC arose from the fast-changing personalized medicine environment amid diminishing research opportunities for junior faculty and increasing demands to pre-screen large populations for the molecular subsets required for study eligibility.

A consortium's collaboration speeds the integration of the latest discoveries from academic laboratories into clinical research. Through collaborative working groups, researchers from Big Ten cancer centers refine scientific curiosity into novel clinical trials, honed by some of the brightest minds in cancer research. This means advances in the fight against cancer translate more efficiently into new treatments for patients.

*"Collaborating with other institutions creates the base for new research ideas; and this is beneficial for institutions. Participating in the Big Ten Cancer Research Consortium offers me an opportunity to share my ideas with nationally recognized breast cancer experts."*

**Oana Danciu, MD**  
University of Illinois Cancer Center

*"The Big Ten CRC is able to harness the collaborative spirit of the member institutions to open dynamic studies very quickly for our patients. I have been fortunate to open one of my trials through the Big Ten CRC and the experience solidified how important organizations like this are for people who are relatively early in their career."*

**Dwight Owen, MD, MSc**  
The Ohio State University

## TOGETHER, THE BIG TEN CANCER CENTERS:

SUPPORT THE WORK OF

**3,000**

RESEARCHERS

CARE FOR

**75k+**

NEW CANCER  
PATIENTS

ENROLL

**30k**

PARTICIPANTS IN  
CLINICAL TRIALS

## SUCCESS STRENGTHENS COLLABORATIONS.

The first Big Ten CRC clinical trial opened in 2015 and completed enrollment 6 months ahead of schedule. This rapid completion means scientific discoveries translate quickly into new approaches to treating our patients with cancer.

The Big Ten CRC actively develops and manages trials across a wide spectrum of cancers.

**400+**

RESEARCHERS  
JOINED CLINICAL  
TRIAL WORKING  
GROUPS

**600+**

PATIENTS  
ENROLLED IN  
BIG TEN CRC  
STUDIES

**30+**

BIG TEN CRC  
CLINICAL TRIALS

**15K+**

SAMPLES  
COLLECTED FOR  
CORRELATIVE  
RESEARCH



“The Big Ten CRC is specifically designed to be nimble, flexible, and very competitive in the modern world of oncology clinical trials.”

— **SALMA JABBOUR, MD, RUTGERS CANCER  
INSTITUTE OF NEW JERSEY**



## **MISSION & VISION**

The Big Ten Cancer Centers united to transform the conduct of cancer research through collaborative clinical trials and observational studies that seek to improve the lives of cancer patients in the diverse communities we serve by leveraging the scientific and clinical expertise of Big Ten universities. The Big Ten Cancer Research Consortium creates a unique team research culture to drive science rapidly from ideas to treatment and prevention. Within this innovative environment, today's research leaders collaborate with and mentor the research leaders of tomorrow.

## **THE BIG TEN CANCER RESEARCH CONSORTIUM...**

**LEVERAGES** respective strengths of academic cancer centers to develop multidisciplinary and deep translational research protocols to enhance the quality and impact of trials.

**PROVIDES** access to a large patient population to facilitate accrual to biologically specialized trials.

**OFFERS** an additional venue for faculty to develop novel protocols.

**ATTRACTS** funding collaborators due to streamlined operations.

**DECREASES** time to publication through multi-center accrual.



## CORE VALUES

### EXPERTISE

#### Team of leaders

From the investigators at our member institutions to the staff at Admin HQ, the Big Ten CRC is built from a team of experts in oncology. Leveraging the expertise of oncologists in clinical trials is crucial for ensuring the safety and efficacy of new cancer treatments.

### INNOVATION

#### Development in clinical trials

Advanced technologies such as genomics and precision medicine are tailoring treatments to individual patients, maximizing effectiveness, and minimizing side effects. Novel trial designs and adaptive approaches are accelerating the drug development process, bringing promising therapies to patients faster and improving overall outcomes in the fight against cancer.

### COLLABORATION

#### Knowledge through teamwork

By pooling the expertise, resources, and patient populations of multiple institutions, our collaborations enhance the diversity of trial participants, leading to more robust and generalizable results. These partnerships foster innovation, accelerate the development of new therapies, and promote the dissemination of knowledge across the medical community, ultimately benefiting patients worldwide.

### MENTORSHIP

#### Inspire the future

Experienced mentors pass on their knowledge and expertise to junior researchers, helping them navigate the intricacies of trial design, patient recruitment, data analysis, and reporting. Mentors help their junior peers develop skills, build confidence, and access opportunities for professional growth, leading to the development of the next generation of experts in the field.



---

## 10 YEARS OF HISTORY


---

Transformative moments throughout history have shaped our future in ways we couldn't have predicted. The Big Ten Cancer Research Consortium celebrates its tenth year in 2023, prompting reflection on milestones achieved and opportunities ahead.

**Established in 2013, the Big Ten CRC has made remarkable contributions to cancer research and care in the past decade. Its story is one of innovation, dedication, and collaboration.**

The consortium's inception was sparked by a moment of creative energy and insight. Dr. Steven T. Rosen, the former director of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, realized the collective power of the Big Ten institutions during an NCI cancer director meeting in Washington.

Dr. Patrick J. Loehrer, Sr., director of the Indiana University Melvin and Bren Simon Cancer Center, recognized the natural fit of the consortium due to the abundance of NCI-designated cancer centers within the Big Ten. The idea of the Big Ten's spirit of collaboration, competitiveness, and collective brain trust emerged as a powerful catalyst for networking and collaboration. Their underlying intent was always to benefit patients. The consortium's early days were fueled by excitement and enthusiasm. A kickoff event during the American Society of Clinical Oncology Annual Meeting in June 2013 left a lasting impression, with attendees describing it as phenomenal.



Competitors became collaborators, exemplifying the consortium's spirit of unity and shared purpose.

The Big Ten Cancer Research Consortium has grown into a prominent player in the cancer research landscape, influencing the direction of oncology research through its trials, publications, and presentations at national and international conferences.

The consortium completed its first trial efficiently and ahead of schedule, turning promise into reality. Dr. Arkadiusz Dudek discussed the results of the Big Ten CRC's inaugural trial during an ASCO 2018 poster session. This achievement demonstrated the consortium's ability to create the necessary infrastructure and deliver on its promise of conducting novel trials efficiently. The consortium has developed a robust portfolio of clinical trials covering a wide range of cancer types and treatment modalities. These trials have contributed to advances in precision medicine, immunotherapy, targeted therapies, and innovative treatment approaches.



The Big Ten CRC's clinical trials have had a significant impact on patient care by providing access to cutting-edge treatments and therapies. Patients within the Big Ten region and beyond have benefited from the consortium's efforts to bring novel treatments and interventions to the clinic.


The Big Ten cancer centers' combined strength instills hope in cancer patients. Together, they support the work of 3,000 cancer researchers, care for over 75,000 new cancer patients annually, and enroll 30,000 patient volunteers in cancer clinical trials.


The consortium's commitment to personalized medicine, innovative treatment approaches, and collaboration between researchers and clinicians has not gone unnoticed. Pharmaceutical companies appreciate the value brought by Big Ten CRC investigators and their ability to conduct high-impact trials, fostering repeat collaborations and building a reputation for producing results in high-visibility trials. As the

consortium continues to strengthen relationships with funding collaborators, we anticipate even more remarkable milestones in the years ahead.

Throughout the last decade all our member institutions have achieved significant milestones, transforming the care we provide to our patients. These accomplishments include expanded patient services, increased funding for genomics and precision medicine studies, and the attainment of comprehensive cancer center status. The collective growth and success of our member institutions bring a wealth of expertise, resources, and diverse patient populations to our unique collaboration.

INSTITUTIONAL MILESTONES





# 10 YEARS OF INNOVATION

---

## CLINICAL TRIAL WORKING GROUPS

---

### COMPETITORS ON THE FIELD, COLLABORATORS IN RESEARCH

The Big Ten Cancer Research Consortium invites investigators from Big Ten institutions to participate in our Clinical Trial Working Groups. Working groups provide investigators with opportunities to:

- Evaluate concepts during the development and design of a protocol.
- Receive input on concepts from key opinion leaders.
- Co-author publications.
- Share best practices in clinical oncology.

Through regular teleconferences and occasional in-person meetings, the working group remains actively engaged throughout the life of Big Ten CRC studies. Fostering an environment of mentorship, these groups are ideal for physicians at all stages in their career.



Follow the QR code to view the schedule of upcoming clinical trial working group calls.



### ADMINISTRATIVE HEADQUARTERS

- Facilitates Clinical Trial Working Groups
- LOI Submission
- Protocol Development Support
- Correlative Research Management
- Project Management
- Regulatory and IND Management
- Safety Reporting
- Contracting, Budgeting, and Payment Processing
- Data Management and Monitoring
- Publication and Presentation Support

### DISEASE SPECIFIC WORKING GROUPS

Share best practices in clinical oncology.

Engage with industry representatives.

Participate in Big Ten CRC Clinical Trials.

Submit an LOI.



**| Adolescent and Young Adult | Basket Trial |**  
**| Bone Marrow/Stem Cell Transplant | Breast Cancer |**  
**| Comparative Oncology | Correlative Sciences |**  
**| Gastrointestinal | Genitourinary |**  
**| Gynecologic | Head and Neck | Lymphoid Malignancies**  
**| Melanoma/Cutaneous Oncology |**  
**| Multiple Myeloma | Myeloid Malignancies |**  
**| Neuro-Oncology | Population Science |**  
**| Sarcoma | Thoracic |**

# 10 YEARS OF CLINICAL TRIALS

## BIG TEN CANCER RESEARCH CONSORTIUM CLINICAL TRIALS

Study	Status	Title	Institutions
BTCRC-AML17-113	Open to Accrual	Phase Ib study of the safety and efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in patients with relapsed or refractory CD33+ acute myeloid leukemia: Big Ten Cancer Research Consortium BTCRC-AML17-113	University of Illinois, Indiana University, University of Nebraska
BTCRC-BRE15-024	Open to Accrual	A phase I/II, single arm, non-randomized study of ribociclib (LEE011), a CDK 4/6 inhibitor in combination with bicalutamide, an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer: Big Ten Cancer Research Consortium BTCRC-BRE15-024	University of Illinois, University of Wisconsin, University of Rochester, Michigan State University, Penn State University, Rutgers University
BTCRC-BRE19-409	Open to Accrual	A Phase II, Single Arm, Non-randomized Study of Alpelisib (BYL719) in Combination with Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer: Big Ten Cancer Research Consortium BTCRC-BRE19-409	University of Illinois, University of Nebraska, Penn State University, University of Wisconsin
BTCRC-GI20-457	Open to Accrual	A Phase II study of Atezolizumab and Bevacizumab in Child-Pugh B7 Hepatocellular Carcinoma (The AB7 Trial): Big Ten Cancer Research Consortium BTCRC-GI20-457	University of Illinois, Indiana University, University of Nebraska, Rutgers University, University of Wisconsin, DHR Health, New York University
BTCRC-HN17-111	Open to Accrual	Phase II Trial of Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma: Big Ten Cancer Research Consortium BTCRC-HN17-111	University of Illinois, University of Iowa, University of Maryland, University of Michigan, University of Minnesota, Northwestern University, University of Wisconsin
BTCRC-LUN18-153	Open to Accrual	A Randomized Phase II Trial of Adjuvant Pembrolizumab Versus Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm: Big Ten Cancer Research Consortium BTCRC-LUN18-153	University of Illinois, Indiana University, University of Iowa, University of Minnesota, University of Nebraska, The Ohio State University, Penn State University, Rutgers University, Moffitt Cancer Center, University of Virginia
BTCRC-LUN18-363	Open to Accrual	A Phase II Study of Chemo-Immunotherapy Followed by Durvalumab (MEDI4736) and Ceralasertib (AZD6738) in Treatment Naive Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC): Big Ten Cancer Research Consortium BTCRC-LUN18-363	University of Illinois, University of Iowa, The Ohio State University, Indiana University, Maryland University
BTCRC-LUN19-396	Open to Accrual	A Phase II Study of Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors $\geq$ 4cm), IIA, IIB, and Select IIIA [T3N1, T4N0-1] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA): Big Ten Cancer Research Consortium BTCRC-LUN19-396	Indiana University, Northwestern University, The Ohio State University, Penn State University, Rutgers University, University of Wisconsin, New York University, University of Virginia, Summit Health
BTCRC-LUN20-462	Open to Accrual	A Randomized, Multi-Cohort Phase II Trial of Temozolomide and Atezolizumab as Second Line Treatment for Small Cell Lung Cancer: Big Ten Cancer Research Consortium BTCRC-LUN20-462	Indiana University, The Ohio State University, University of Wisconsin, University of Iowa
BTCRC-LYM20-463	Open to Accrual	A Single Arm Phase I/II Study of Tazemetostat with Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma: Big Ten Cancer Research Consortium BTCRC-LYM20-463	University of Illinois, Rutgers University, The Ohio State University, University of Wisconsin
BTCRC-BRE15-016	Closed to Accrual	A Single Arm Phase II Study of Palbociclib in Combination with Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer: Big Ten Cancer Research Consortium BTCRC-BRE15-016	University of Illinois, Michigan State University, University of Minnesota, University of Nebraska, Penn State University, University of Wisconsin
BTCRC-BRE16-042	Closed to Accrual	A Phase II Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients: Big Ten Cancer Research Consortium BTCRC-BRE16-042	Michigan State University, University of Nebraska, Rutgers University, University of Wisconsin, New York University
BTCRC-BRE18-337	Closed to Accrual	Phase 2 Trial With Safety Run-In of Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers: Big Ten Cancer Research Consortium BTCRC-BRE18-337	University of Illinois, Indiana University, University of Iowa, Northwestern University, University of Wisconsin
BTCRC-GI15-015	Closed to Accrual	A Phase II Study of FOLFOX combined with Nab-Paclitaxel (FOLFOX-A) in the Treatment of Metastatic or Advanced Unresectable Gastric, Gastro-Esophageal Junction Adenocarcinoma: Big Ten Cancer Research Consortium BTCRC-GI15-015	University of Illinois, University of Iowa, Michigan State University, University of Minnesota, Northwestern University, Rutgers University, University of Wisconsin
BTCRC-GI15-067	Closed to Accrual	A phase II study to evaluate the efficacy of liposomal irinotecan in combination with oxaliplatin, leucovorin, and 5-fluorouracil for patients with locally advanced pancreatic carcinoma: Big Ten Cancer Research Consortium BTCRC-GI15-067	Indiana University, Northwestern University, Penn State University, Rutgers University
BTCRC-HEM15-027	Closed to Accrual	Phase I Study of Nivolumab in Combination with Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma: Big Ten Cancer Research Consortium BTCRC-HEM15-027	University of Iowa, University of Minnesota, University of Wisconsin

Study	Status	Title	Institutions
BTCRC-LUN15-017	Closed to Accrual	A Phase Ib/II Study of Anti-PD-1 Antibody Pembrolizumab and Imprime PGG for Patients with Metastatic Non-small Cell Lung Cancer After Progression on First-Line Chemotherapy: Big Ten Cancer Research Consortium BTCRC-LUN15-017	University of Illinois, University of Iowa, Rutgers University
BTCRC-LUN16-081	Closed to Accrual	Phase II Study of Consolidation Immunotherapy with Nivolumab and Ipilimumab or Nivolumab alone following Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC): Big Ten Cancer Research Consortium BTCRC-LUN16-081	University of Illinois, Indiana University, Michigan State University, University of Minnesota, Penn State University, Rutgers University, University of Nebraska, University of Wisconsin, Rush University, Johns Hopkins University, University of Louisville, Karmanos
BTCRC-LUN17-127	Closed to Accrual	A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer: Big Ten Cancer Research Consortium BTCRC-LUN17-127	University of Illinois, City of Hope, Henry Ford, University of Minnesota, Rutgers University, University of Iowa, Moffit Cancer Center, Indiana University
BTCRC-LYM17-145	Closed to Accrual	Phase Ib dose de-escalation study of the PI3K alpha/delta inhibitor, Copanlisib given in combination with the immunotherapeutic agents, Nivolumab and Rituximab in patients with relapsed/refractory indolent Lymphoma: Big Ten Cancer Research Consortium BTCRC-LYM17-145	University of Michigan, University of Nebraska, Rutgers University, University of Illinois
BTCRC-ESO14-012	Completed	A Phase II Study Evaluating Safety and Efficacy of Durvalumab (MEDI4736) Following Multi-modality Therapy in Esophageal Cancer: Big Ten Cancer Research Consortium BTCRC-ESO14-012	Indiana University, University of Iowa University of Michigan
BTCRC-GU14-003	Completed	Phase Ib and Phase II Studies of Anti-PD-1 Antibody MK-3475 in Combination With Bevacizumab for the Treatment of Metastatic Renal Cell Carcinoma: Big Ten Cancer Research Consortium GU14-003	University of Illinois, Indiana University, University of Iowa, University of Michigan, Michigan State University, University of Minnesota, University of Nebraska, Penn State University, Rutgers University, University of Wisconsin
BTCRC-GU15-023	Completed	Phase Ib/II Study of Concurrent Durvalumab And Radiation Therapy (DUART) Followed by Adjuvant Durvalumab in Patients with Urothelial Cancer (T2-4 NO-2 MO) of the Bladder: Big Ten Cancer Research Consortium GU15-023	University of Iowa, Penn State, University of Wisconsin, Montefiore Medical Center, Methodist Hospital, Froedtert and the Medical College of Wisconsin
BTCRC-GU16-043	Completed	Single Arm Phase Ib/II Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer: Big Ten Cancer Research Consortium BTCRC-GU16-043	University of Illinois, University of Iowa, University of Michigan, Penn State University, Rutgers University
BTCRC-GYN15-013	Completed	Phase II Study of Pembrolizumab in Combination With Carboplatin and Paclitaxel for Advanced or Recurrent Endometrial Adenocarcinoma: Big Ten Cancer Research Consortium BTCRC-GYN15-013	Indiana University, University of Iowa, University of Minnesota, Northwestern University, Ironwood Cancer and Research Centers
BTCRC-LUN15-029	Completed	A Phase II Trial of Chemotherapy plus Pembrolizumab in patients with advanced NSCLC previously treated with PD-1 or PD-L1 Inhibitor: Big Ten Cancer Research Consortium BTCRC-LUN15-029	University of Illinois, Indiana University, University of Iowa, University of Minnesota, University of Wisconsin
BTCRC-LUN17-139	Completed	A Phase II Study of Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-naïve Patients With Stage IV Non-squamous Non-small Cell Lung Cancer: Big Ten Cancer Research Consortium BTCRC-LUN17-139	University of Illinois Cancer Center, Indiana University, University of Iowa, Rutgers University, University of Wisconsin, University of Virginia Cancer Center
BTCRC-AML18-342	Terminated Early	Phase I trial of azacitidine plus nivolumab following reduced-intensity allogeneic PBSC transplantation for patients with AML and high-risk myelodysplasia. Big Ten Cancer Research Consortium BTCRC-AML18-342	University of Illinois, Indiana University, University of Iowa
BTCRC-GI13-002	Terminated Early	An Open Label Randomized Phase I/II Trial of MLN0128 Compared to Sorafenib in Patients With Advanced or Metastatic Hepatocellular Carcinoma: Big Ten Cancer Research Consortium BTCRC-GI13-002	University of Illinois, Indiana University, University of Michigan, University of Nebraska, Northwestern University, Penn State University, University of Wisconsin, UNC Lineberger Comprehensive Cancer Center
BTCRC-GI18-149	Terminated Early	Phase II Study of the Combination of Abemaciclib and Pembrolizumab in Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma: Big Ten Cancer Research Consortium BTCRC-GI18-149	Indiana University, University of Iowa, Northwestern University, Rutgers University, University of Wisconsin
BTCRC-GI19-400	Terminated Early	Prospective assessment of patients with neuroendocrine tumors and current or prior history of carcinoid syndrome or diarrhea undergoing peptide receptor radionuclide therapy with or without telotristat ethyl (NET-PACS Trial): Big Ten Cancer Research Consortium BTCRC-GI19-400	University of Iowa, Penn State University
BTCRC-GU16-051	Terminated Early	Phase 1b Clinical Trial of Eribulin Mesylate and the PD-L1 Monoclonal Antibody, Avelumab, in Cisplatin Ineligible Metastatic Urothelial Cell Cancer Patients: Big Ten Cancer Research Consortium BTCRC-GU16-051	University of Iowa, Penn State University
BTCRC-HEM15-028	Terminated Early	Phase I/II Study of Ixazomib and Romidepsin in Relapsed/ Refractory Peripheral T-cell Lymphoma (PTCL): Big Ten Cancer Research Consortium BTCRC-HEM15-028	University of Illinois, Indiana University, University of Iowa, University of Michigan, University of Minnesota, Rutgers University, Barbara Ann Karmanos Cancer Center
BTCRC-HEM16-085	Terminated Early	Phase II study of nivolumab and the antagonistic CSF-1R monoclonal antibody cabiralizumab (BMS-986227) in patients with relapsed/refractory peripheral T cell lymphoma: Big Ten Cancer Research Consortium BTCRC-HEM16-085	University of Michigan, The Ohio State University, University of Wisconsin
BTCRC-GU19-404	Terminated Early	A Single Arm, Phase I/II Trial of Neoadjuvant Androgen Deprivation, Darolutamide, and Ipatasertib in Men with Localized, High Risk Prostate Cancer: Big Ten Cancer Research Consortium BTCRC-GU19-404	Indiana University, Northwestern University
BTCRC-HEM17-092	Terminated Early	Phase I/II study augmenting TAK-659 action in relapsed/refractory AML by addition of the proteasome inhibitor Ixazomib: Big Ten Cancer Research Consortium BTCRC-HEM17-092	Indiana University

---

# MEETING POSTERS & PRESENTATIONS

---

## BREAST CANCER

### **BTCRC-BRE15-016**

SABCS 2019 Poster  
ASCO 2021 Posters (2)  
ASCO 2022 Publication

### **BTCRC-BRE15-024**

SABCS 2018 Ongoing Trials

### **BTCRC-BRE16-042**

SABCS 2021 Ongoing Trials

### **BTCRC-BRE18-337**

SABCS 2019 Ongoing Trials  
ASCO 2022 Publication

### **BTCRC-BRE19-409**

ASCO 2022 Trials in Progress

## GASTROINTESTINAL

### **BTCRC-ESO14-012**

ASCO GI 2018 Trials in Progress  
ASCO 2018 Publication  
ASCO GI 2019 Rapid Abstract  
ASCO 2019 Poster  
ASCO GI 2020 Poster  
ASCO 2020 Poster

### **BTCRC-GI15-015**

ASCO GI 2022 Poster

### **BTCRC-GI18-149**

ASCO GI 2020 Trials in Progress

### **BTCRC-GI20-457**

ASCO GI 2022 Trials in Progress

## GENITOURINARY

### **BTCRC-GUI4-003**

ASCO GU 2016 Poster  
ASCO 2018 Poster

### **BTCRC-GUI5-023**

ASCO GU 2020 Poster  
ASTRO 2020 Oral Scientific Session  
ASCO GU 2021 Rapid Abstract

### **BTCRC-GUI6-043**

ESMO 2020 Poster  
ASCO GU 2021 Poster  
ASCO GU 2023 Poster

### **BTCRC-GUI9-404**

ASCO GU 2022 Trials in Progress  
ASCO 2023 Trials in Progress

## GYNECOLOGIC

### **BTCRC-GYN15-103**

ASCO 2020 Poster Discussion

## HEAD AND NECK

### **BTCRC-HN17-111**

ASCO 2022 Publication

## MYELOID

### **BTCRC-AML17-113**

ASCO 2020 Poster  
AACR 2021 Poster

## THORACIC

### **BTCRC-LUN15-017**

WCLC 2018 Poster  
WCLC 2020 Posters (2)

### **BTCRC-LUN15-029**

ASCO 2021 Poster

### **BTCRC-LUN16-081**

SITC 2018 Trials in Progress  
ASCO 2019 Poster  
ASCO 2020 Poster Discussion  
ASCO 2022 Poster Discussion  
ASCO 2022 Publication  
ASCO 2023 Poster

### **BTCRC-LUN17-127**

ASCO 2021 Poster

### **BTCRC-LUN17-139**

ASCO 2021 Poster

### **BTCRC-LUN18-153**

ASCO 2021 Poster

### **BTCRC-LUN19-396**

WCLC 2020 Poster  
ASCO 2022 Trials in Progress

## RENAL CELL CARCINOMA (2020)

### Phase Ib/II Clinical Trial of Pembrolizumab With Bevacizumab for Metastatic Renal Cell Carcinoma: BTCRC-GU14-003

Authors: Arkadiusz Z. Dudek (Illinois-Chicago), Li C. Liu (Illinois-Chicago), Shilpa Gupta (Minnesota), Theodore F. Logan (Indiana), Eric A. Singer (Rutgers), Monika Joshi (Penn State), Yousef N. Zakharia (Iowa), Joshua M. Lang (Wisconsin), James K. Schwarz (Nebraska), Anas Al-Janadi (Michigan State), Ajjai S. Alva (Michigan)

DOI: 10.1200/JCO.19.02394 Journal of Clinical Oncology 38, no. 11 (April 10, 2020) 1138-1145.



## UROTHELIAL CARCINOMA (2021)

### Avelumab in Combination with Eribulin Mesylate in Metastatic Urothelial Carcinoma: BTCRC GU-051, a Phase 1b Study

Authors: Monika Joshi (Penn State), Sheldon L. Holder (Penn State), Junjia Zhu (Penn State), Hong Zheng (Penn State), Shraddha Komanduri (Penn State), Joshua Warrick (Penn State), Hesham Yasin (Iowa), Rohan Garje (Iowa), Bei Jia (Penn State), Joseph J. Drabick (Penn State), David J. DeGraff (Penn State), Yousef Zakharia (Iowa)

DOI: <https://doi.org/10.1016/j.euf.2021.03.005>



## ESOPHAGEAL/GEJ ADENOCARCINOMA (2021)

### A Phase II Trial of Adjuvant Durvalumab Following Trimodality Therapy for Locally Advanced Esophageal and Gastroesophageal Junction Adenocarcinoma: A Big Ten Cancer Research Consortium Study

Authors: Hirva Mamdani (Karmanos), Bryan Schneider (Michigan), Susan M. Perkins (Indiana), Heather N. Burney (Indiana), Pashtoon Murtaza Kasi (Iowa), Laith I. Abushahin (Ohio State), Thomas Birdas (Indiana), Kenneth Kesler (Indiana), Tracy M. Watkins (Indiana), Sunil S. Badve (Indiana), Milan Radovich (Indiana), Shadia I. Jalal (Indiana)

Front. Oncol. 11:736620.  
doi: 10.3389/fonc.2021.736620



# JOURNAL MANUSCRIPTS

## POPULATION SCIENCE (2023)

### Current Approaches to Serving Catchment Areas in Cancer Centers: Insights from the Big Ten Cancer Research Consortium Population Science Working Group

Authors: Sharon L. Manne (Rutgers), Cheryl L. Knott (Maryland), Ann Berger (Nebraska), Victoria L. Champion (Indiana), Elizabeth Chrischilles (Iowa), Marian L. Fitzgibbon (Illinois-Chicago), Anita Y. Kinney (Rutgers), Eugene J. Lengerich (Penn State), Sarah H. Nash (Iowa), Melissa A. Simon (Northwestern), Amy Trentham-Dietz (Wisconsin), Electra D. Paskett (Ohio State)

Cancer Epidemiol Biomarkers Prev.  
2023 Apr 3;32(4):465-472.  
doi: 10.1158/1055-9965.EPI-22-0958.



## UROTHELIAL CARCINOMA (2023)

### Concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder: results from phase II study, BTCRC-GU15-023

Authors: Monika Joshi (Penn State), Leonard Tuanquin (Penn State), Junjia Zhu (Penn State), Vonn Walter (Penn State), Todd Schell (Penn State), Matthew Kaag (Penn State), Deepak Kilari (Medical College of Wisconsin), Jiangang Liao (Penn State), Sheldon L. Holder (Penn State), Hamid Emamekhoo (Wisconsin), Alexander Sankin (Montefiore), Suzzane Merrill (Penn State), Hong Zheng (Penn State), Joshua Warrick (Penn State), Ralph Hauke (Nebraska Cancer Specialists), Benjamin Gartrel (Montefiore), Mark Stein (Columbia), Joseph Drabick (Penn State), David J. DeGraff (Penn State), Yousef Zakharia (Iowa)

Journal for ImmunoTherapy of Cancer  
2023;11:e006551. doi: 10.1136/jitc-2022-006551



---

## 10 YEARS OF COLLABORATION

---

The Big Ten Cancer Research Consortium provides investigators multifaceted opportunities. Beyond the capacity to launch or join a clinical trial, it provides an extensive platform to disseminate innovative research with other institutions through our Virtual Grand Rounds.

The consortium also offers avenues for philanthropic support for research proposals, encouraging the pursuit of novel and impactful projects in the field of oncology. Philanthropic groups, corporations, and individuals are encouraged to contact the Big Ten CRC to discuss opportunities to support Big Ten CRC research.

---



### KENNETH AND VERNA MAE JESSEN AWARD

In 2022, The Big Ten Cancer Research Consortium Foundation, Inc., awarded Edward M. Greenfield, PhD, the \$100,000 Kenneth and Verna Mae Jessen Award. Dr. Greenfield is a member of the tumor microenvironment and metastasis research program at the

Indiana University Melvin and Bren Simon Comprehensive Cancer Center and professor of orthopaedic surgery at IU School of Medicine. The Big Ten Cancer Research Consortium established the Kenneth and Verna Mae Jessen Award after a generous donation of \$100,000 from the Verna Mae Jessen Trust. The trust supports nonprofit organizations working in cancer or pain management research.

---

## VIRTUAL GRAND ROUNDS

---

The Big Ten CRC Virtual Grand Rounds is a virtual meeting held monthly and hosted by our member institutions.

These educational events are hosted live for faculty investigators, scientists, fellows, residents, medical students, and clinical research staff. Typical attendance ranges between 50-100 researchers from multiple institutions.

New collaborations between cancer centers in the Big Ten have emerged from these discussions. Industry representatives may subscribe to attend Big Ten CRC Grand Rounds.

Visit [www.bigtenrc.org/grand-rounds-subscription/](http://www.bigtenrc.org/grand-rounds-subscription/)

---

**The goal of the Big Ten CRC Grand Rounds is to expand awareness, dialogue, and opportunities for collaboration between member institutions.**



In 2023, the Big Ten Cancer Research Consortium launched "Bridging the Gap," a podcast hosted by the Big Ten CRC Diversity Committee that features talks with investigators, industry collaborators, and patient advocates. Themes center around how to work together to develop policies and strategic priorities for the Big Ten CRC that will foster growth, learning, and change to create a more equitable environment for patients enrolled in clinical trials. The Big Ten Cancer Research Consortium Diversity Committee is composed of investigators from our member institutions across disease types.

In the first episode, the co-chairs discuss the plans they would like to tackle as a group. This includes improving health equity through access to clinical trials, increasing awareness and opportunities for clinical trial participation among underrepresented populations, providing expanded resources for investigators to encourage travel (ex., attendance at conferences), and fostering relationships with minority healthcare associations and other groups to bring new perspectives to clinical research.

The Big Ten Cancer Research Consortium recognizes the importance of racial, ethnic, and gender diversity in clinical trial participation. Together, and individually, we are committed to actively working toward clinical trial development and participation that reflects the demographics of disease in our subgroups. We recognize the need for outreach to all patient populations to emphasize the positive benefits gained from participation in clinical trials, and for collaborative efforts to remove the social and economic barriers that prevent individuals from participating in clinical research.

### **Co-Chairs of the Big Ten Cancer Research Consortium Diversity Committee**

---



**Coral O. Omene, MD, PhD**  
Rutgers Cancer Institute of  
New Jersey



**Craig Cole, MD**  
Michigan State University

---



Administrative Headquarters at  
Hoosier Cancer Research Network  
7676 Interactive Way, Suite 120  
Indianapolis, IN 46278

**phone:** 317-921-2050, ext. 43  
**[www.bigtenrc.org](http://www.bigtenrc.org)**